: People with cystic fibrosis (CF) suffer from recurrent bacterial infections which induce inflammation, lung tissue damage and failure of the respiratory system. Prolonged exposure to combinatorial antibiotic therapies triggers the appearance of multi-drug resistant (MDR) bacteria. The development of alternative antimicrobial strategies may provide a way to mitigate antimicrobial resistance. Here we discuss different alternative approaches to the use of classic antibiotics: anti-virulence and anti-biofilm compounds which exert a low selective pressure; phage therapies that represent an alternative strategy with a high therapeutic potential; new methods helping antibiotics activity such as adjuvants; and antimicrobial peptides and nanoparticle formulations. Their mechanisms and in vitro and in vivo efficacy are described, in order to figure out a complete landscape of new alternative approaches to fight MDR Gram-negative CF pathogens.

New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis

Scoffone, Viola Camilla;Barbieri, Giulia;Irudal, Samuele;Trespidi, Gabriele;Buroni, Silvia
2024-01-01

Abstract

: People with cystic fibrosis (CF) suffer from recurrent bacterial infections which induce inflammation, lung tissue damage and failure of the respiratory system. Prolonged exposure to combinatorial antibiotic therapies triggers the appearance of multi-drug resistant (MDR) bacteria. The development of alternative antimicrobial strategies may provide a way to mitigate antimicrobial resistance. Here we discuss different alternative approaches to the use of classic antibiotics: anti-virulence and anti-biofilm compounds which exert a low selective pressure; phage therapies that represent an alternative strategy with a high therapeutic potential; new methods helping antibiotics activity such as adjuvants; and antimicrobial peptides and nanoparticle formulations. Their mechanisms and in vitro and in vivo efficacy are described, in order to figure out a complete landscape of new alternative approaches to fight MDR Gram-negative CF pathogens.
2024
Microbiology covers the biology and biochemistry of microorganisms, bacterial, viral, and parasitic, as well as the medical implications and treatments of the subset of these organisms known to cause disease in humans and/or animals. Biotechnology applications of microorganisms for basic science or clinical use are also covered. Resources that emphasize immune response to pathogens and its modulation by clinical intervention are excluded and are covered in the Immunology category.
Esperti anonimi
Inglese
Internazionale
13
1
Gram-negative pathogens; adjuvants; alternative antimicrobial strategies; anti-virulence compounds; antimicrobial peptides; cystic fibrosis; nanoparticles; phage therapy
5
info:eu-repo/semantics/article
262
Scoffone, Viola Camilla; Barbieri, Giulia; Irudal, Samuele; Trespidi, Gabriele; Buroni, Silvia
1 Contributo su Rivista::1.1 Articolo in rivista
open
File in questo prodotto:
File Dimensione Formato  
antibiotics.pdf

accesso aperto

Dimensione 2.73 MB
Formato Adobe PDF
2.73 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1490195
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 15
social impact